X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3667) 3667
Publication (602) 602
Newsletter (163) 163
Newspaper Article (27) 27
Book Chapter (25) 25
Book Review (25) 25
Conference Proceeding (12) 12
Magazine Article (9) 9
Dissertation (4) 4
Trade Publication Article (3) 3
Paper (2) 2
Transcript (2) 2
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
dasatinib (3397) 3397
humans (2442) 2442
index medicus (2165) 2165
oncology (1398) 1398
imatinib (1099) 1099
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (996) 996
hematology (977) 977
chronic myeloid leukemia (891) 891
female (885) 885
male (854) 854
imatinib mesylate (851) 851
nilotinib (824) 824
pyrimidines - therapeutic use (823) 823
protein kinase inhibitors - therapeutic use (805) 805
chronic myelogenous leukemia (786) 786
chronic myeloid-leukemia (717) 717
middle aged (678) 678
antineoplastic agents - therapeutic use (666) 666
cancer (661) 661
thiazoles - therapeutic use (629) 629
protein kinase inhibitors - pharmacology (607) 607
pyrimidines - pharmacology (594) 594
adult (589) 589
animals (579) 579
aged (545) 545
leukemia (535) 535
benzamides (534) 534
research (512) 512
thiazoles - pharmacology (466) 466
hemic and lymphatic diseases (465) 465
cell line, tumor (460) 460
tyrosine (445) 445
treatment outcome (434) 434
bcr-abl (432) 432
piperazines - therapeutic use (423) 423
care and treatment (419) 419
therapy (412) 412
tyrosine kinase inhibitors (409) 409
protein-tyrosine kinases - antagonists & inhibitors (408) 408
mutation (387) 387
mice (386) 386
tyrosine kinase inhibitor (382) 382
antineoplastic agents - pharmacology (370) 370
pyrimidines - adverse effects (352) 352
drug therapy (339) 339
pyrimidines - administration & dosage (323) 323
drug resistance, neoplasm (318) 318
article (315) 315
resistance (314) 314
leukemia, myelogenous, chronic, bcr-abl positive - genetics (313) 313
pharmacology & pharmacy (311) 311
fusion proteins, bcr-abl - genetics (306) 306
protein kinase inhibitors - adverse effects (304) 304
cml (295) 295
analysis (288) 288
follow-up (280) 280
kinases (274) 274
tyrosine kinase (269) 269
chronic-phase (262) 262
protein kinase inhibitors - administration & dosage (257) 257
aged, 80 and over (248) 248
thiazoles - adverse effects (248) 248
activation (245) 245
thiazoles - administration & dosage (244) 244
antineoplastic agents - adverse effects (242) 242
dosage and administration (237) 237
chemotherapy (236) 236
health aspects (234) 234
phosphorylation (233) 233
apoptosis (227) 227
leukemia, myelogenous, chronic, bcr-abl positive - pathology (226) 226
hematology, oncology and palliative medicine (225) 225
medicine & public health (225) 225
src-family kinases - antagonists & inhibitors (224) 224
antineoplastic agents (220) 220
young adult (216) 216
fusion proteins, bcr-abl - antagonists & inhibitors (215) 215
src-family kinases - metabolism (214) 214
dasatinib - therapeutic use (211) 211
src (211) 211
in-vitro (210) 210
cell proliferation - drug effects (209) 209
expression (208) 208
apoptosis - drug effects (207) 207
genetic aspects (207) 207
cytogenetic responses (202) 202
piperazines - pharmacology (202) 202
cell biology (194) 194
abridged index medicus (193) 193
antimitotic agents (192) 192
philadelphia chromosome (192) 192
cells (190) 190
antineoplastic agents - administration & dosage (188) 188
dasatinib - pharmacology (188) 188
imatinib-resistant (188) 188
kinase inhibitor (188) 188
protein-tyrosine kinase (182) 182
signal transduction - drug effects (178) 178
antineoplastic combined chemotherapy protocols - therapeutic use (177) 177
adolescent (176) 176
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3659) 3659
Japanese (54) 54
Chinese (28) 28
French (28) 28
Polish (25) 25
Russian (22) 22
Spanish (17) 17
German (14) 14
Czech (9) 9
Korean (9) 9
Portuguese (6) 6
Turkish (6) 6
Danish (2) 2
Hebrew (2) 2
Italian (2) 2
Slovenian (2) 2
Finnish (1) 1
Hungarian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 5915 - 5915
Abstract Introduction Survival outcomes for patients with lymphoid, myeloid and plasma cell malignancies, have improved with the use of oral small molecule... 
Journal Article
Biosensors and Bioelectronics, ISSN 0956-5663, 12/2016, Volume 86, pp. 879 - 884
Journal Article
Journal Article
Science, ISSN 0036-8075, 07/2019, Volume 365, Issue 6448, p. 41
Journal Article
Journal Article
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 05/2019, Volume 17, Issue 5, pp. 611 - 613
The NCCN Guidelines for Chronic Myeloid Leukemia (CML) criteria for discontinuation of tyrosine kinase inhibitor (TKI) therapy have not seen significant... 
ONCOLOGY | IMATINIB | DASATINIB
Journal Article
Cancer, ISSN 0008-543X, 03/2016, Volume 122, Issue 6, pp. 868 - 874
Journal Article
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 07/2017, Volume 258, pp. 43 - 55
Two novel prodrug polymers POEG- -PSSDas (redox-sensitive) and POEG- -PCCDas (redox-insensitive), which consist of poly(oligo(ethylene glycol) methacrylate)... 
Prodrug micelles | Dasatinib | Redox responsive | Co-delivery | Doxorubicin | DESIGN | DRUG-DELIVERY | OVARIAN-CANCER | ANTITUMOR-ACTIVITY | CHEMISTRY, MULTIDISCIPLINARY | CHRONIC MYELOID-LEUKEMIA | PACLITAXEL | BREAST-CANCER CELLS | FAMILY KINASE INHIBITOR | IMATINIB | PHARMACOLOGY & PHARMACY | MULTIDRUG-RESISTANCE | Prodrugs - administration & dosage | Doxorubicin - therapeutic use | Humans | Dasatinib - pharmacokinetics | Delayed-Action Preparations - chemistry | Polyethylene Glycols - chemistry | Drug Delivery Systems | Micelles | Female | Antibiotics, Antineoplastic - pharmacokinetics | Doxorubicin - administration & dosage | Protein Kinase Inhibitors - pharmacokinetics | Cell Survival - drug effects | Oxidation-Reduction | Dasatinib - therapeutic use | Doxorubicin - pharmacokinetics | Neoplasms - drug therapy | Antibiotics, Antineoplastic - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Animals | Dasatinib - administration & dosage | Antibiotics, Antineoplastic - therapeutic use | Prodrugs - pharmacokinetics | Protein Kinase Inhibitors - therapeutic use | Cell Line, Tumor | Mice, Inbred BALB C | Prodrugs - therapeutic use | Neoplasms - pathology | Ethylene glycol | Anthracyclines | Chemotherapy | Polymers | Analysis | Cancer | Tyrosine | Medical colleges | Pharmacogenetics | Pharmacy | Physiological aspects | Drugstores | co-delivery | dasatinib | doxorubicin | prodrug micelles | redox responsive
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 2/2016, Volume 72, Issue 2, pp. 185 - 193
Dasatinib is a novel, oral, multi-targeted kinase inhibitor of breakpoint cluster region-abelson (BCR-ABL) and Src family kinases. The study investigated... 
Dasatinib | Pharmacodynamics | Biomedicine | Half maximal inhibitory concentration | Phamacokinetics | Pharmacology/Toxicology | Molecular response | CELLS | SAFETY | TYROSINE KINASE | NILOTINIB | PHILADELPHIA-CHROMOSOME | IMATINIB | DRUGS | BCR-ABL ACTIVITY | PHARMACOLOGY & PHARMACY | INHIBITOR | Leukocytes, Mononuclear - metabolism | Antigens, CD34 - metabolism | Oncogene Protein v-crk - antagonists & inhibitors | Humans | Middle Aged | Oncogene Protein v-crk - metabolism | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Dasatinib - pharmacokinetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Phosphorylation - drug effects | Protein Kinase Inhibitors - pharmacokinetics | Leukocytes, Mononuclear - drug effects | Dasatinib - therapeutic use | Treatment Outcome | Dasatinib - pharmacology | Fusion Proteins, bcr-abl - genetics | Protein Kinase Inhibitors - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Aged | Dasatinib - adverse effects | Protein Kinase Inhibitors - pharmacology | Phosphotransferases | Analysis | Chronic myeloid leukemia | Pharmacology | Kinetics | Drug therapy | Leukemia | Chronic illnesses
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 09/2016, Volume 126, Issue 9, pp. 3207 - 3218
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 05/2019, Volume 60, Issue 6, pp. 1568 - 1571
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 02/2017, Volume 35, Issue 5
Journal Article
Cancer, ISSN 0008-543X, 12/2015, Volume 121, Issue 23, pp. 4158 - 4164
BACKGROUND The long‐term efficacy of a combination of chemotherapy and dasatinib in patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic... 
dasatinib | acute lymphoblastic leukemia | chemotherapy | combination | Philadelphia chromosome | ADULT PATIENTS | ACUTE LYMPHOCYTIC-LEUKEMIA | REGIMEN | HYPER-CVAD | PONATINIB | THERAPY | ONCOLOGY | IMATINIB | MRD | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Cytarabine - therapeutic use | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Methotrexate - therapeutic use | Cyclophosphamide - therapeutic use | Neoplasm, Residual | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Philadelphia Chromosome | Doxorubicin - administration & dosage | Dexamethasone - administration & dosage | Dasatinib - therapeutic use | Treatment Outcome | Cytarabine - administration & dosage | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Dexamethasone - therapeutic use | Dasatinib - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Vincristine - therapeutic use | Methotrexate - administration & dosage | Aged | Dasatinib | Chemotherapy | Usage | Care and treatment | Lymphocytic leukemia | Stem cells | Dosage and administration | Transplantation | Diagnosis | Cancer
Journal Article